- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02971995
Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies (PROSTEPIRM)
Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies in Prostate Cancer Patients
Prostate cancer is the first cancer in humans (25%). The most widely used tracer in oncology, the 18-Fluoro DeoxyGlucose does not allow the study of prostatic neoplasia. On the other hand, Choline, which is an amino alcohol, is involved in the synthesis of cell membranes and has an affinity for prostate cells. Its concentration is directly proportional to cell proliferation. The analogue of choline has the advantage of having a rapid and stable accumulation over time in cancer cells, with a rapid urinary excretion (4 minutes after injection).
The goal of this study is to assess the feasibility and the accuracy for targeting image guided prostate biopsy to detect prostate cancer after Imaging fusion of choline-PET/CT compared to 1.5T multiparametric magnetic resonance imaging (mpMRI) with 3D-transrectal ultrasound (TRUS) .
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with suspicion of prostate cancer
- Patients who performed prostate mpMRI and F-Choline 18 PET scan
- Patient capable of receiving clear informations
- Patient giving a written consent for their participation via a consent signed by both parents of the patient (or legal tutor)
- Patient covered by a healthcare insurance
Exclusion Criteria:
- Patients without suspect image of neoplasia after mpMRI and F-Choline 18 PET scan
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prostate cancer/TEP scan
|
Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy
|
Active Comparator: Prostate cancer/mpMRI
|
Performance of the mpMRI in order to determine the place where to take the biopsy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of image guided prostate biopsy in the zones detected by the TEP scan
Time Frame: at inclusion
|
at inclusion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of image guided prostate biopsy in the zones detected by the mpMRI
Time Frame: at inclusion
|
at inclusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jean Louis Bonnal, MD, GHICL
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OBS025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasm
-
National Cancer Institute (NCI)CompletedProstatic Neoplasms | Prostate Cancer | Neoplasm, Prostate | Neoplasm,ProstaticUnited States
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterCompletedProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Neoplasm of Uncertain BehaviorUnited States
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
-
Centre Hospitalier Universitaire de BesanconRecruiting
-
Fondazione del Piemonte per l'OncologiaCompleted
-
AbbottCompletedProstatic NeoplasmBelgium, Luxembourg
-
Mayo ClinicCompletedProstatic NeoplasmUnited States
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompleted
-
Advanced Accelerator ApplicationsTerminatedProstatic NeoplasmUnited States, Spain
-
Sismanoglio General HospitalNational and Kapodistrian University of AthensCompletedProstatic NeoplasmGreece
Clinical Trials on PET Scan ou TEP-TDM
-
Institut Cancerologie de l'OuestActive, not recruiting
-
Institut BergoniéCompletedCancer Disease Progression
-
Assistance Publique - Hôpitaux de ParisCompletedColorectal CancerFrance
-
University Hospital, ToulouseInstitut National de la Santé Et de la Recherche Médicale, FranceWithdrawn
-
Institut du Cancer de Montpellier - Val d'AurelleCompletedHead and Neck Cancer | Oesophageal CancerFrance
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompletedHepatocellular CarcinomaFrance
-
Université de SherbrookeNestlé Health Science SpainCompletedKetoses, MetabolicCanada
-
Duke UniversityRecruitingEsophageal Cancer | Vulvar Cancer | Anal Canal Cancer | Cancer of the CervixUnited States
-
University of Texas Southwestern Medical CenterActive, not recruitingTesticular Germ Cell Tumor | Testicular Neoplasms | Testicular Diseases | Testis Cancer | Testicular Cancer | Germ Cell Tumor | Testicular Yolk Sac Tumor | Testicular Choriocarcinoma | Germ Cell Tumor of Testis | Germ Cell Tumor, Testicular, Childhood | Germ Cell Cancer Metastatic | Germ Cell Neoplasm of Retroperitoneum and other conditionsUnited States
-
University of OklahomaMidwest Medical IsotopesTerminatedNon-Hodgkin's LymphomaUnited States